Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database

por Bagegni, Nusayba A., Tao, Yu, Ademuyiwa, Foluso O.
Publicado 2019

Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab

por Bagegni, Nusayba A, Davis, Andrew A, Clifton, Katherine K, Ademuyiwa, Foluso O
Publicado 2022

Management of Diarrhea in Patients with HER2-Positive Breast Cancer Treated with Neratinib: A Case Series and Summary of the Literature

por Kruse, Megan L., Kang, Irene M., Bagegni, Nusayba A., Howell, W. Todd, Moore, Halle C. F., Bedell, Cynthia H., Stokoe, Christopher T.
Publicado 2021

Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors

por Bagegni, Nusayba A., Park, Haeseong, Kraft, Katlyn, O-Toole, Maura, Gao, Feng, Waqar, Saiama N., Ratner, Lee, Morgensztern, Daniel, Devarakonda, Siddhartha, Amin, Manik, Baggstrom, Maria Q., Liang, Chris, Selvaggi, Giovanni, Wang-Gillam, Andrea
Publicado 2022

Radiation-Induced Brachial Plexopathy in Patients With Breast Cancer Treated With Comprehensive Adjuvant Radiation Therapy

por Rudra, Soumon, Roy, Amit, Brenneman, Randall, Gabani, Prashant, Roach, Michael C., Ochoa, Laura, Prather, Heidi, Appleton, Catherine, Margenthaler, Julie, Peterson, Lindsay L., Bagegni, Nusayba A., Zoberi, Jacqueline E., Garcia-Ramirez, Jose, Thomas, Maria A., Zoberi, Imran
Publicado 2020

Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib

por Bagegni, Nusayba, Thomas, Shana, Liu, Ning, Luo, Jingqin, Hoog, Jeremy, Northfelt, Donald W., Goetz, Matthew P., Forero, Andres, Bergqvist, Mattias, Karen, Jakob, Neumüller, Magnus, Suh, Edward M., Guo, Zhanfang, Vij, Kiran, Sanati, Souzan, Ellis, Matthew, Ma, Cynthia X.
Publicado 2017

TIPS-19 TRIAL IN PROGRESS: SECONDARY BRAIN METASTASES PREVENTION AFTER ISOLATED INTRACRANIAL PROGRESSION ON TRASTUZUMAB/PERTUZUMAB OR T-DM1 IN PATIENTS WITH ADVANCED HUMAN EPIDERMA...

por Van Swearingen, Amanda, Sammons, Sarah, Noteware, Laura, Bagegni, Nusayba, Moulton, Kelly, Threatt, Stevie, Jaggers, Denise, Shea, Shannon, Lipp, Eric, Riley, Erin, Jung, Sin-Ho, Broadwater, Gloria, Ross, Masey, Strickland, Kimberly, Beyer, Sasha, Conlin, Alison, Morikawa, Aki, Murthy, Rashmi, Anders, Carey
Publicado 2023

A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN)

por Ademuyiwa, Foluso O., Northfelt, Donald W., O’Connor, Tracey, Levine, Ellis, Luo, Jingqin, Tao, Yu, Hoog, Jeremy, Laury, Marie L., Summa, Tracy, Hammerschmidt, Trish, Guo, Zhanfang, Frith, Ashley, Weilbaecher, Katherine, Opyrchal, Mateusz, Aft, Rebecca, Clifton, Katherine, Suresh, Rama, Bagegni, Nusayba, Hagemann, Ian S., Iglesia, Michael D., Ma, Cynthia X.
Publicado 2023

Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer

por Davis, Andrew A., Gerratana, Lorenzo, Clifton, Katherine, Medford, Arielle J., Velimirovic, Marko, Hensing, Whitney L., Bucheit, Leslie, Shah, Ami N., D'Amico, Paolo, Reduzzi, Carolina, Zhang, Qiang, Dai, Charles S., Denault, Elyssa N., Bagegni, Nusayba A., Opyrchal, Mateusz, Ademuyiwa, Foluso O., Bose, Ron, Gradishar, William J., Behdad, Amir, Ma, Cynthia X., Bardia, Aditya, Cristofanilli, Massimo
Publicado 2022

Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential

por Wong, Terrence N., Miller, Christopher A., Jotte, Matthew R. M., Bagegni, Nusayba, Baty, Jack D., Schmidt, Amy P., Cashen, Amanda F., Duncavage, Eric J., Helton, Nichole M., Fiala, Mark, Fulton, Robert S., Heath, Sharon E., Janke, Megan, Luber, Kierstin, Westervelt, Peter, Vij, Ravi, DiPersio, John F., Welch, John S., Graubert, Timothy A., Walter, Matthew J., Ley, Timothy J., Link, Daniel C.
Publicado 2018